Antitumor effect of combining STING agonist (ADU-S100) and Doxorubicin versus Doxorubicin alone or control vehicle in mouse sarcoma cell line (WEHI-164)

Doxorubicin treatment induces the expression of proinflammatory cytokines through the activation of the STING pathway. Our study demonstrates that the combined administration of the STING agonist ADU-S100 significantly enhances the antitumor efficacy of doxorubicin in a syngeneic mouse model of sarcoma using the WEHI-164 cell line. Overall design: RNA-seq profiling was performed on CD45+ cells magnetically sorted from dissected tumors treated with: 1) ADU-S100 and doxorubicin, 2) doxorubicin alone, and 3) the control.